LinkGevity Announces Investment from the KQ Labs Programme Delivered by the Francis Crick Institute — First-in-Class Anti-Necrotic Therapeutic set to initiate clinical trials for kidney disease and accelerated aging in 2025
London, UK, 22 January 2025 – LinkGevity, an AI-driven drug discovery company focused on age-related diseases and longevity, today announces it has been selected for the prestigious KQ Labs Programme, delivered by the Francis Crick Institute, Europe’s largest biomedical research centre.
The KQ Labs Programme provides participants with an equity investment, and access to an advanced global scientific network. Only 10 startups are chosen annually, after a rigorous due diligence process, for this highly selective initiative that is aimed at propelling world class healthcare innovations forward. LinkGevity’s therapeutic data, innovative approach and scientific leadership secured its place in this elite cohort.
